Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib dose-escalation in advanced NSCLC
NCT00072631Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Nov 2003
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by OSI Pharmaceuticals. Primary endpoints: Feasibility of intrapatient dose escalation of erlotinib HCI to introduce a characteristic, target rash at 3 years and Objective Response Rate at 3 years. Started Nov 2003; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00072631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072631.